How tesamorelin targets visceral fat: the mechanism
The short version: a stabilized signal asks the pituitary for more growth hormone — and growth hormone preferentially trims fat from around the organs.
TL;DR
- Tesamorelin is a stabilized GHRH analog: it copies the body’s natural “release growth hormone, please” signal.
- Trials show it reduces visceral fat — the fat surrounding internal organs — more than it reduces subcutaneous fat.
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Compounded tesamorelin preparations used outside that indication are not FDA-approved.
What it is
Tesamorelin (in plain English: a slightly modified version of the body’s growth-hormone-releasing hormone, designed to last longer in the bloodstream than the natural version) was approved by the FDA in 2010 under the brand name Egrifta, for HIV-associated lipodystrophy (FDA Egrifta label, 2010). The same active ingredient is sometimes prepared by 503A compounding pharmacies for off-label clinical use; compounded preparations themselves are not FDA-approved.
How it works
Think of the pituitary gland as a small post office at the base of the brain. GHRH (growth-hormone-releasing hormone — in plain English: the body’s “release growth hormone, please” letter) tells the post office to send out growth hormone. The body’s own GHRH breaks down quickly. Tesamorelin is a slightly redesigned version of the same letter — same address, same message, just written on sturdier paper. The post office gets the signal and sends out a normal pulse of growth hormone. Growth hormone then travels to the liver and tissues, raises IGF-1 (insulin-like growth factor 1), and shifts how the body uses fat (Falutz et al., NEJM, 2007).
Who asks about it
People come to this topic after reading that tesamorelin is studied for visceral fat — the deep belly fat that surrounds the liver, pancreas, and intestines. They want to understand why this peptide preferentially affects that fat and not, say, fat under the skin.
What the research says
The pivotal phase 3 trial — published in the New England Journal of Medicine — showed that 26 weeks of tesamorelin reduced visceral adipose tissue by about 15% in people with HIV-associated lipodystrophy, with smaller effects on subcutaneous fat (Falutz et al., NEJM, 2007). The mechanism is consistent across studies: higher pulsatile growth hormone mobilizes visceral fat preferentially. About 4 in 10 participants in the trials saw substantial visceral fat changes; the response is real but not universal.
What to know before considering it
Tesamorelin can raise IGF-1 above the age-adjusted reference range. Clinicians monitor IGF-1, fasting glucose, and HbA1c. People with active malignancy or uncontrolled diabetes are typically excluded from this kind of protocol. Compounded tesamorelin used off-label is not FDA-approved.
The Halftime POV
Tesamorelin is one of the few peptides in this space with a phase-3 randomized trial behind it. The mechanism is clean — copy the body’s own signal, more durably — and the published outcomes are specific. That makes it a useful baseline for how to talk about peptide effects honestly.
Related reading:
- Tesamorelin: the FDA-approved GHRH analog explained
- Tesamorelin and visceral fat research
- How sermorelin signals growth hormone release
FAQ
Q: How does tesamorelin work? A: Tesamorelin is a stabilized GHRH analog. It binds the GHRH receptor on the pituitary and signals it to release more growth hormone, which then raises IGF-1. The downstream effect studied in clinical trials is reduction in visceral fat.
Q: Is tesamorelin FDA-approved? A: Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy. Compounded tesamorelin preparations used outside that indication are not FDA-approved.
Q: Why does tesamorelin reduce visceral fat? A: Higher pulsatile growth hormone preferentially mobilizes visceral adipose tissue in published trials, lowering visceral fat without an equivalent loss of subcutaneous fat.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
